Financials in USD. Standardized financial statements.
A compact view of how Scinai Immunotherapeutics Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.31M | $658,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +99.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $3.96M | $1.24M | $512,675 | $559,801 | $747,649 | $708,920 | $461,688 | $72,317 | $123,554 | $0 |
| Gross Profit? | -$2.65M | -$580,000 | -$512,675 | -$559,801 | -$747,649 | -$708,920 | $0 | $0 | $0 | $0 |
| Gross Margin? | -202.3% | -88.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $4.89M | $8.06M | $9.71M | $11.06M | $10.86M | -$2.28M | $22.69M | $20.61M | $6.80M | $3.09M |
| Operating Income? | -$7.54M | -$8.64M | -$9.71M | -$11.06M | -$10.87M | $2.28M | -$22.69M | -$20.61M | -$6.80M | -$3.09M |
| EBITDA? | -$6.53M | -$6.99M | -$9.19M | -$10.50M | -$10.39M | $2.75M | -$22.21M | -$20.54M | -$6.67M | -$2.93M |
| Income Before Tax | -$8.31M | $4.80M | -$6.50M | -$5.80M | -$8.21M | -$1.39M | -$31.62M | -$23.46M | -$9.93M | -$2.38M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$8.31M | $4.80M | -$6.50M | -$5.80M | -$8.21M | -$1.39M | -$31.62M | -$23.46M | -$9.93M | -$2.38M |
| EPS? | $-3.60 | $6.00 | $-16.80 | $-30.80 | $-80.00 | $-12.40 | $-1548800.00 | $-1435800.00 | $-790280.00 | $-282320.00 |
| Diluted EPS? | $-3.60 | $6.00 | $-16.80 | $-30.80 | $-80.00 | $-12.40 | $-1548800.00 | $-1435800.00 | $-790280.00 | $-282320.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality